For years, scientists have hoped to harness the immune system to attack cancer using a group of drugs known as CD40 agonist ...

VU grad wins Fulbright grant Micah Koppang, a 2025 Valparaiso University graduate, has been selected for a Fulbright scholarship. Koppang, a Spanish major with a minor in political science who ...

Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

Vascular toxicity associated with cancer therapies is a leading cause of cardiovascular adverse events in patients with ...

Private equity firm THL Partners has agreed to buy a majority stake in Headlands Research, a U.S.-based network of clinical ...

By Rishika Sadam and Bhanvi Satija (Reuters) -Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...